Weekly profile.NORTH AMERICAN SCIENTIFIC INC inc - /ink/ increment, i.e. increase by one. Especially used by assembly programmers, as many assembly languages have an "inc" mnemonic. Antonym: dec. . Symbol: NASI (1) (NetWare Asynchronous Service Interface) A protocol from Novell for connecting to modems in a communications server. It was derived from the NCSI protocol. NASI provides more advanced features than the common int 14 (interrupt 14) method. Exchange: NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on Close: $9.17 1-WK % Chg: -1.9% Business Overview North American Scientific Inc., incorporated in 1995, manufactures and markets a line of radioisotopic products for medical, scientific and industrial uses. The company's primary products are brachytherapy seeds for the treatment of prostate cancer and radioactive reference sources used to calibrate To adjust or bring into balance. Scanners, CRTs and similar peripherals may require periodic adjustment. Unlike digital devices, the electronic components within these analog devices may change from their original specification. See color calibration and tweak. a variety of medical and commercial equipment. North American Scientific markets and sells Iodine-125 implantable brachytherapy seeds, marketed under the trade name Prospera I-125, and Palladium-103 implantable brachytherapy seeds, under the trade name Prospera Pd-103. The company is also engaged in the research and development of a novel, proprietary radiopharmaceutical radiopharmaceutical /ra·dio·phar·ma·ceu·ti·cal/ (-fahr?mah-soo´ti-k'l) a radioactive pharmaceutical, nuclide, or other chemical used for diagnostic or therapeutic purposes. imaging agent known as Hynic-Annexin V. The candidate agent is an in vivo nuclear, medicine imaging agent that targets cells undergoing apoptosis or necrosis, two common forms of cell death. Income Statement 2003 * 2002 Revenue (millions) $14.7 $20.8 Operating Loss (10.9) (2.3) Net Loss (9.4) (5.2) Loss Per Share ($0.92) ($0.51) Summary Headquarters: Chatsworth Market Cap: $94.7 million Dividend Yield: None P/E Ratio: NA ** * Fiscal years ended on Oct. 31. ** Company is not profitable. [GRAPHIC OMITTED] |
|
||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion